238 related articles for article (PubMed ID: 35595416)
1. Therapeutic Drug Monitoring of Biologics in Crohn's Disease.
Grossberg LB; Cheifetz AS; Papamichael K
Gastroenterol Clin North Am; 2022 Jun; 51(2):299-317. PubMed ID: 35595416
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
5. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
6. Updates in therapeutic drug monitoring in inflammatory bowel disease.
Lodhia N; Rao S
World J Gastroenterol; 2022 Jun; 28(21):2282-2290. PubMed ID: 35800180
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K; Afif W; Drobne D; Dubinsky MC; Ferrante M; Irving PM; Kamperidis N; Kobayashi T; Kotze PG; Lambert J; Noor NM; Roblin X; Roda G; Vande Casteele N; Yarur AJ; Arebi N; Danese S; Paul S; Sandborn WJ; Vermeire S; Cheifetz AS; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):171-185. PubMed ID: 35026171
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Papamichael K; Cheifetz AS
Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
[TBL] [Abstract][Full Text] [Related]
9. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place.
Truta B
World J Gastroenterol; 2022 Apr; 28(13):1380-1383. PubMed ID: 35645545
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient.
Nones RB; Fleshner PR; Queiroz NSF; Cheifetz AS; Spinelli A; Danese S; Peyrin-Biroulet L; Papamichael K; Kotze PG
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884344
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
14. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
15. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.
Lega S; Bramuzzo M; Dubinsky MC
Curr Med Chem; 2018; 25(24):2840-2854. PubMed ID: 28901267
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
[TBL] [Abstract][Full Text] [Related]
18. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
19. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.
Yao J; Jiang X; You JHS
J Gastroenterol Hepatol; 2021 Sep; 36(9):2397-2407. PubMed ID: 33326123
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F; Argüelles-Arias F; Hinojosa Del Val J; Iborra Colomino M; Martín-Arranz MD; Menchén Viso L; Muñoz Núñez F; Ricart Gómez E; Sánchez-Hernández JG; Valdés-Delgado T; Guardiola Capón J; Barreiro-de Acosta M; Mañosa Ciria M; Zabana Abdo Y; Gutiérrez Casbas A
Gastroenterol Hepatol; 2024 May; 47(5):522-552. PubMed ID: 38311005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
